Experience:
1-3 years of experience
Concerned about your lack of experience? Learn More...
Employment Type:
Full time
Posted:
7/6/2017
Job Category:
Science
See more jobs for students and recent grads who studied:
Clinical Data Scientist, Research and Early Development
Biogen | Cambridge, Massachusetts
Tell Us More About Your Job Preferences
By telling us what you think of this job, we can help find jobs that match your interests. If you want to see more jobs like this, click on the smiley face. Or if this job isn't what you are looking for, click the frowny face. Learn More...

Follow This Company
Share

Job Description

External Posting TitleClinical Data Scientist, Research and Early Development
Job DescriptionBiogen is actively developing and employing digital patient assessment technologies in clinical
trials to support development of its pipeline of neurodegenerative and neurological disease
clinical candidates.
We are looking to hire a Data Scientist with expertise in Neuroscience to participate in and
drive projects that investigate the use of wearable technology in clinical trials of
neurodegenerative disease populations.
The successful candidate will report to the Vice President, Neurology Early Clinical
Development, with a focus on Movement Disorders (Parkinson's disease and related diseases).
He/se will work closely with the VP, program medical directors and clinician-scientists as well
as other external and internal business partners on all aspects of the projects, including
experiment design, sensor selection, data quality control, algorithm development and data
analysis.
Responsibilities:
- Lead efforts to identify, evaluate and qualify quantitative clinical assessment
technologies to support clinical development programs
- Build analysis pipelines to process data collected from multiple wearable sensors
- Develop novel algorithms for the analysis of multi-dimensional time series data
- Build predictive models and perform ensemble modeling
- Evaluate different wearable technologies and provide data driven solutions to help
determine optimal technology to deploy in clinical trials
- Develop wearable device endpoints for early phase clinical trials
- Work with external collaborators and technology companies on leveraging existing big
data platforms and optimizing them for Biogen's specific needs
- Contribute to experimental design for clinical trial protocols and proof of concept
studies
- Analyze in house datasets to illuminate current and future studies

*LI-RD2
LocationCambridge, MA, US
Job CategoryClinical Development, Research
Requisition Number31943BR
Qualifications- Proven experience in algorithm development, signal processing, time series analysis,
frequency domain analysis, and machine learning is required
- Fluency in two of the following data analysis tools is required: R, Python and/or MATLAB
- Solid background in mathematics and statistics is required
- Research experience in neurological disease areas, especially Movement Disorders,
kinesiology or related disciplines is preferred
- Experience with clinical experimental design, and/or with early phase clinical trials
- A keen interest in machine learning and deep learning methods is a plus
- Experience integrating data from multiple modalities is a plus
- Comfort with ambiguity and a problem-solving aptitude
- Excellent communication and presentation skills; Ability to communicate highly
technical work to a diverse audience
- Experience working in highly matrixed teams
-Minimum 3 years experience post Ph.D and at least 1 year in industry (pharma, tech development) preferred
EducationPhD in Neuroscience, Computer Science, Engineering or related field
About BiogenCorporate Overview

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis (MS), has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS). Biogen also manufactures and commercializes biosimilars of advanced biologics. Our global organization of nearly 7,000 employees is committed to a single mission: making a meaningful difference in the lives of patients with few or no treatment options.

One of the pioneers in biotechnology, Biogen was founded in 1978 and today serves patients in nearly 90 countries. Our global headquarters and R&D operations are located in Cambridge, Massachusetts, with an international headquarters in Zug, Switzerland, world-class manufacturing facilities in Research Triangle Park, North Carolina, USA and Hillerod, Denmark, and affiliate locations around the world.

Our Science

We aspire to have the greatest impact on patients and science of any biotechnology company in the history of our industry. To us, that means creating novel medicines that benefit individuals and society, and bringing new scientific understanding to diseases for which there are no adequate treatments.

For nearly two decades Biogen has led in the research and development of new therapies to treat MS, including the most prescribed oral treatment in the world. Now our research is driving revolutionary new MS treatments with the goal of reversing or even repairing damage caused by the disease. We are now applying our neurological expertise to solve some of most challenging and complex diseases of the brain, including Alzheimer's disease, Parkinson's disease, and ALS. As we uncover new insights into human biology, Biogen is employing cutting-edge technologies to discover potential treatments for rare and genetic disorders.

Biogen is revolutionizing biologics manufacturing, developing the industry's most advanced plants and processes. This expertise is used to produce both original innovative therapies and biosimilars that expand patient access to lower-cost medicines.

Our Corporate Citizenship

The same intellectual discipline and passion that drives our science is reflected in our corporate citizenship, environmental sustainability, and commitment to diversity and inclusion. As a company, we are focused on improving science education and limiting the impact of our company on the environment. In 2015, we became a carbon neutral company and ranked first place on Newsweek's 2015 Green Rankings, and we are an industry leader on the Dow Jones Sustainability World Index. Biogen was named to Science's list of Top Employers of 2015 and in 2017 received a perfect score of 100 for the fourth consecutive year on the Human Rights Campaign (HRC) Corporate Equality Index, which also named Biogen as one of its Best Places to Work.

All qualified applicants will receive consideration for employment without regard to sex, gender identity or expression, sexual orientation, marital status, race, color, national origin, ancestry, ethnicity, religion, age, veteran status, disability, genetic information or any other basis protected by federal, state or local law. Biogen is an E-Verify Employer in the United States.

Please be advised that all legitimate correspondence from a Biogen employee will come from "@biogen.com" email accounts.

About Biogen

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company's products address diseases such as multiple sclerosis, lymphoma and rheumatoid arthritis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is used in the treatment of relapsed or refractory low-grade or follicular, CD20-positive, and B-cell, non-Hodgkin's lymphomas (B-cell NHLs). TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. It also has product candidates, such as BG-12 (acquired with the purchase of Fumapharm), ANTI-CD80 antibody/(galiximab), ANTI-CD23 antibody/(lumiliximab), Ocrelizumab/(Humanized ANTI-CD20 Antibody) and Lixivaptan.In January 2007, the Company completed the acquisition of Syntonix Pharmaceuticals, Inc. (Source: 10-K)

This company profile was created by AfterCollege and is about Biogen. This page is not endorsed by or affiliated with Biogen. For questions regarding company profiles, please email: care@aftercollege.com.